Reuters logo
BRIEF-Keryx Biopharmaceuticals jumps in premarket after kidney disease drug meets trial goal
January 28, 2013 / 12:35 PM / in 5 years

BRIEF-Keryx Biopharmaceuticals jumps in premarket after kidney disease drug meets trial goal

NEW YORK, Jan 28 (Reuters) - Keryx Biopharmaceuticals Inc : * Keryx Biopharma jumps 46.4 percent to $5.02 in premarket after kidney disease drug meets late-stage trial goal

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below